A Phase IIIB/IV Randomised Open-label Trial to Compare Dolutegravir + Pharmaco-enhanced Darunavir Versus Recommended Standard of Care Antiretroviral Regimens in Patients With HIV Infection Who Have Failed Recommended First Line Therapy.
Not yet recruiting
Phase of Trial: Phase III/IV
Latest Information Update: 06 Sep 2017
At a glance
- Drugs Dolutegravir (Primary) ; Darunavir/ritonavir; Nucleoside reverse transcriptase inhibitors
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms D2EFT
- 30 Aug 2017 Planned End Date changed from 1 Dec 2020 to 30 Sep 2020.
- 30 Aug 2017 Planned primary completion date changed from 1 Aug 2019 to 30 Sep 2019.
- 30 Aug 2017 Planned initiation date changed from 1 Jul 2017 to 30 Sep 2017.